Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
R Roskoski Jr - Pharmacological research, 2019 - Elsevier
The EGFR family is among the most investigated receptor protein-tyrosine kinase groups
owing to its general role in signal transduction and in oncogenesis. This family consists of …
owing to its general role in signal transduction and in oncogenesis. This family consists of …
The ErbB/HER family of protein-tyrosine kinases and cancer
R Roskoski Jr - Pharmacological research, 2014 - Elsevier
The human epidermal growth factor receptor (EGFR) family consists of four members that
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
belong to the ErbB lineage of proteins (ErbB1–4). These receptors consist of a glycosylated …
BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese …
Purpose The phase III BEYOND trial was undertaken to confirm in a Chinese patient
population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy …
population the efficacy seen with first-line bevacizumab plus platinum doublet chemotherapy …
[HTML][HTML] Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
X Liu, P Wang, C Zhang, Z Ma - Oncotarget, 2017 - ncbi.nlm.nih.gov
Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …
of noncoding RNA regulatory networks has been more and more reveal. EGFR has been …
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
R Roskoski Jr - Pharmacological research, 2014 - Elsevier
The epidermal growth factor receptor (EGFR) family consists of four members that belong to
the ErbB lineage of proteins (ErbB1–4). These receptors consist of an extracellular domain …
the ErbB lineage of proteins (ErbB1–4). These receptors consist of an extracellular domain …
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …
[HTML][HTML] Molecular pathways and therapeutic targets in lung cancer
E Shtivelman, T Hensing, GR Simon, PA Dennis… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
molecularly lung cancer is heterogeneous. This review summarizes the current knowledge …
[HTML][HTML] Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for …
Y Zhang, J Sheng, S Kang, W Fang, Y Yan, Z Hu… - PloS one, 2014 - journals.plos.org
Backgrounds It has been extensively proved that the efficacy of epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
receptor-tyrosine kinase inhibitors (EGFR-TKIs) is superior to that of cytotoxic chemotherapy …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …